About Molecular chaperone MKKS
Molecular chaperone MKKS (MKKS) is a protein
from Homo sapiens identified by UniProt accession
Q9NPJ1, 570 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | Molecular chaperone MKKS |
| UniProt accession | Q9NPJ1 |
| Gene | MKKS |
| Organism | Homo sapiens |
| Length | 570 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (119)
Diseases linked to this target (Open Targets).
- McKusick-Kaufman syndrome · score 0.81
- Bardet-Biedl syndrome · score 0.75
- genetic disorder · score 0.52
- Retinal dystrophy · score 0.46
- Polydactyly · score 0.46
- polydactyly · score 0.46
- nephronophthisis · score 0.42
- Obesity · score 0.37
- ciliopathy · score 0.37
- Bardet-Biedl syndrome 1 · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NPJ1-F1 | alphafold | PREDICTED | 88.96 | — |
Amino-acid sequence (570 residues)
MSRLEAKKPS LCKSEPLTTE RVRTTLSVLK RIVTSCYGPS GRLKQLHNGF GGYVCTTSQS SALLSHLLVT HPILKILTAS IQNHVSSFSD CGLFTAILCC NLIENVQRLG LTPTTVIRLN KHLLSLCISY LKSETCGCRI PVDFSSTQIL LCLVRSILTS KPACMLTRKE TEHVSALILR AFLLTIPENA EGHIILGKSL IVPLKGQRVI DSTVLPGILI EMSEVQLMRL LPIKKSTALK VALFCTTLSG DTSDTGEGTV VVSYGVSLEN AVLDQLLNLG RQLISDHVDL VLCQKVIHPS LKQFLNMHRI IAIDRIGVTL MEPLTKMTGT QPIGSLGSIC PNSYGSVKDV CTAKFGSKHF FHLIPNEATI CSLLLCNRND TAWDELKLTC QTALHVLQLT LKEPWALLGG GCTETHLAAY IRHKTHNDPE SILKDDECTQ TELQLIAEAF CSALESVVGS LEHDGGEILT DMKYGHLWSV QADSPCVANW PDLLSQCGCG LYNSQEELNW SFLRSTRRPF VPQSCLPHEA VGSASNLTLD CLTAKLSGLQ VAVETANLIL DLSYVIEDKN
Explore Molecular chaperone MKKS with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets